Status:
COMPLETED
Study of XL999 in Adults With Solid Tumors
Lead Sponsor:
Symphony Evolution, Inc.
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.
Eligibility Criteria
Inclusion
- Advanced solid tumor
- Cancer that has progressed on currently available therapies
- Life expectancy of \>3 months
- Adequate bone marrow, liver, and kidney function
- Willing to use accepted method of contraception during the course of the study
- Negative pregnancy test (females)
- Written informed consent
Exclusion
- Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
- Radiotherapy within 4 weeks of the start of treatment
- Subjects with known brain metastasis
- Uncontrolled medical disorder such as infection or cardiovascular disease
- Subjects known to be HIV positive
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00104117
Start Date
November 1 2004
End Date
October 1 2008
Last Update
February 19 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Case Western Reserve University, Univserzity Hospitals of Cleveland
Cleveland, Ohio, United States, 44106
2
Cancer Therapy and Research Center, Institute for Drug Development
San Antonio, Texas, United States, 78229